Cargando…

Nomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma

OBJECTIVE: The purpose of this study was to construct nomograms for the disease-free survival (DFS) and overall survival (OS) of post-radiofrequency ablation (RFA) patients with hepatocellular carcinoma (HCC). Furthermore, we compared the prognostic predictive ability of these nomograms for estimati...

Descripción completa

Detalles Bibliográficos
Autores principales: Takuma, Yoshitaka, Shota, Iwadou, Miyatake, Hirokazu, Uematsu, Shuji, Okamoto, Ryouichi, Araki, Yasuyuki, Takabatake, Hiroyuki, Morimoto, Youichi, Yamamoto, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849539/
https://www.ncbi.nlm.nih.gov/pubmed/29151504
http://dx.doi.org/10.2169/internalmedicine.9064-17
_version_ 1783306052232544256
author Takuma, Yoshitaka
Shota, Iwadou
Miyatake, Hirokazu
Uematsu, Shuji
Okamoto, Ryouichi
Araki, Yasuyuki
Takabatake, Hiroyuki
Morimoto, Youichi
Yamamoto, Hiroshi
author_facet Takuma, Yoshitaka
Shota, Iwadou
Miyatake, Hirokazu
Uematsu, Shuji
Okamoto, Ryouichi
Araki, Yasuyuki
Takabatake, Hiroyuki
Morimoto, Youichi
Yamamoto, Hiroshi
author_sort Takuma, Yoshitaka
collection PubMed
description OBJECTIVE: The purpose of this study was to construct nomograms for the disease-free survival (DFS) and overall survival (OS) of post-radiofrequency ablation (RFA) patients with hepatocellular carcinoma (HCC). Furthermore, we compared the prognostic predictive ability of these nomograms for estimating per-patient outcomes with that of traditional staging systems. METHODS: We retrospectively enrolled 298 patients in the training set and 272 patients in the validation set who underwent RFA for HCC. The nomograms for the DFS and OS were constructed from the training set using the multivariate Cox proportional hazards model. The discriminatory accuracy of the models was compared with traditional staging systems by analyzing the Harrell's C-index. RESULTS: The DFS nomogram was developed based on the tumor size, tumor number, aspartate aminotransferase (AST), albumin, age, and α-fetoprotein. The OS nomogram was developed based on the tumor size, the model for end-stage liver disease, AST, and albumin. Our DFS and OS nomograms had good calibration and discriminatory abilities in the training set, with C-indexes of 0.640 and 0.692, respectively, that were greater than those of traditional staging systems. The C-indexes of our DFS and OS nomograms were also greater than those of traditional staging systems in the validation set, with C-indexes of 0.614 and 0.657, respectively. RFA patients were stratified into low- and high-risk groups based on the median nomogram scores. High-risk patients receiving surgical resection (SR) were associated with a better DFS and OS than those undergoing RFA. However, the DFS and OS were similar between the low-risk RFA and SR groups. CONCLUSION: We constructed reliable and useful nomograms that accurately predict the DFS and OS after RFA for early-stage HCC patients. These graphical tools are easy to use and will assist physicians during the therapeutic decision-making process.
format Online
Article
Text
id pubmed-5849539
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-58495392018-03-15 Nomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma Takuma, Yoshitaka Shota, Iwadou Miyatake, Hirokazu Uematsu, Shuji Okamoto, Ryouichi Araki, Yasuyuki Takabatake, Hiroyuki Morimoto, Youichi Yamamoto, Hiroshi Intern Med Original Article OBJECTIVE: The purpose of this study was to construct nomograms for the disease-free survival (DFS) and overall survival (OS) of post-radiofrequency ablation (RFA) patients with hepatocellular carcinoma (HCC). Furthermore, we compared the prognostic predictive ability of these nomograms for estimating per-patient outcomes with that of traditional staging systems. METHODS: We retrospectively enrolled 298 patients in the training set and 272 patients in the validation set who underwent RFA for HCC. The nomograms for the DFS and OS were constructed from the training set using the multivariate Cox proportional hazards model. The discriminatory accuracy of the models was compared with traditional staging systems by analyzing the Harrell's C-index. RESULTS: The DFS nomogram was developed based on the tumor size, tumor number, aspartate aminotransferase (AST), albumin, age, and α-fetoprotein. The OS nomogram was developed based on the tumor size, the model for end-stage liver disease, AST, and albumin. Our DFS and OS nomograms had good calibration and discriminatory abilities in the training set, with C-indexes of 0.640 and 0.692, respectively, that were greater than those of traditional staging systems. The C-indexes of our DFS and OS nomograms were also greater than those of traditional staging systems in the validation set, with C-indexes of 0.614 and 0.657, respectively. RFA patients were stratified into low- and high-risk groups based on the median nomogram scores. High-risk patients receiving surgical resection (SR) were associated with a better DFS and OS than those undergoing RFA. However, the DFS and OS were similar between the low-risk RFA and SR groups. CONCLUSION: We constructed reliable and useful nomograms that accurately predict the DFS and OS after RFA for early-stage HCC patients. These graphical tools are easy to use and will assist physicians during the therapeutic decision-making process. The Japanese Society of Internal Medicine 2017-11-20 2018-02-15 /pmc/articles/PMC5849539/ /pubmed/29151504 http://dx.doi.org/10.2169/internalmedicine.9064-17 Text en Copyright © 2018 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Takuma, Yoshitaka
Shota, Iwadou
Miyatake, Hirokazu
Uematsu, Shuji
Okamoto, Ryouichi
Araki, Yasuyuki
Takabatake, Hiroyuki
Morimoto, Youichi
Yamamoto, Hiroshi
Nomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma
title Nomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma
title_full Nomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma
title_fullStr Nomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma
title_full_unstemmed Nomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma
title_short Nomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma
title_sort nomograms to predict the disease-free survival and overall survival after radiofrequency ablation for hepatocellular carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849539/
https://www.ncbi.nlm.nih.gov/pubmed/29151504
http://dx.doi.org/10.2169/internalmedicine.9064-17
work_keys_str_mv AT takumayoshitaka nomogramstopredictthediseasefreesurvivalandoverallsurvivalafterradiofrequencyablationforhepatocellularcarcinoma
AT shotaiwadou nomogramstopredictthediseasefreesurvivalandoverallsurvivalafterradiofrequencyablationforhepatocellularcarcinoma
AT miyatakehirokazu nomogramstopredictthediseasefreesurvivalandoverallsurvivalafterradiofrequencyablationforhepatocellularcarcinoma
AT uematsushuji nomogramstopredictthediseasefreesurvivalandoverallsurvivalafterradiofrequencyablationforhepatocellularcarcinoma
AT okamotoryouichi nomogramstopredictthediseasefreesurvivalandoverallsurvivalafterradiofrequencyablationforhepatocellularcarcinoma
AT arakiyasuyuki nomogramstopredictthediseasefreesurvivalandoverallsurvivalafterradiofrequencyablationforhepatocellularcarcinoma
AT takabatakehiroyuki nomogramstopredictthediseasefreesurvivalandoverallsurvivalafterradiofrequencyablationforhepatocellularcarcinoma
AT morimotoyouichi nomogramstopredictthediseasefreesurvivalandoverallsurvivalafterradiofrequencyablationforhepatocellularcarcinoma
AT yamamotohiroshi nomogramstopredictthediseasefreesurvivalandoverallsurvivalafterradiofrequencyablationforhepatocellularcarcinoma